Wells Fargo & Company MN trimmed its holdings in shares of Clovis Oncology Inc (NASDAQ:CLVS) by 4.6% in the fourth quarter, according to the company in its most recent filing with the SEC. The institutional investor owned 260,592 shares of the biopharmaceutical company’s stock after selling 12,502 shares during the quarter. Wells Fargo & Company MN owned 0.53% of Clovis Oncology worth $17,720,000 as of its most recent filing with the SEC.
A number of other hedge funds and other institutional investors have also bought and sold shares of CLVS. Orbimed Advisors LLC increased its stake in Clovis Oncology by 13.5% during the 3rd quarter. Orbimed Advisors LLC now owns 2,388,670 shares of the biopharmaceutical company’s stock worth $196,826,000 after purchasing an additional 284,300 shares in the last quarter. Sectoral Asset Management Inc grew its stake in shares of Clovis Oncology by 689.0% during the 3rd quarter. Sectoral Asset Management Inc now owns 251,699 shares of the biopharmaceutical company’s stock worth $20,740,000 after acquiring an additional 219,799 shares in the last quarter. Macquarie Group Ltd. grew its stake in shares of Clovis Oncology by 56.0% during the 3rd quarter. Macquarie Group Ltd. now owns 526,880 shares of the biopharmaceutical company’s stock worth $43,415,000 after acquiring an additional 189,211 shares in the last quarter. Sector Gamma AS bought a new position in shares of Clovis Oncology during the 3rd quarter worth approximately $12,203,000. Finally, Westfield Capital Management Co. LP grew its stake in shares of Clovis Oncology by 45.8% during the 3rd quarter. Westfield Capital Management Co. LP now owns 459,470 shares of the biopharmaceutical company’s stock worth $37,860,000 after acquiring an additional 144,300 shares in the last quarter.
In other news, insider Gillian C. Ivers-Read sold 3,000 shares of the stock in a transaction that occurred on Friday, December 15th. The stock was sold at an average price of $64.16, for a total value of $192,480.00. Following the completion of the sale, the insider now owns 182,583 shares of the company’s stock, valued at approximately $11,714,525.28. The transaction was disclosed in a legal filing with the SEC, which is available at this link. Also, Director Thorlef Spickschen sold 4,500 shares of the stock in a transaction that occurred on Monday, January 8th. The shares were sold at an average price of $64.97, for a total value of $292,365.00. Following the completion of the sale, the director now directly owns 21,118 shares of the company’s stock, valued at approximately $1,372,036.46. The disclosure for this sale can be found here. In the last three months, insiders sold 22,500 shares of company stock valued at $1,371,210. 12.50% of the stock is currently owned by insiders.
Shares of Clovis Oncology Inc (NASDAQ CLVS) opened at $62.50 on Monday. The company has a current ratio of 7.69, a quick ratio of 7.35 and a debt-to-equity ratio of 0.77. Clovis Oncology Inc has a twelve month low of $45.42 and a twelve month high of $99.45.
Clovis Oncology (NASDAQ:CLVS) last released its quarterly earnings data on Monday, February 26th. The biopharmaceutical company reported ($1.04) EPS for the quarter, beating the consensus estimate of ($1.29) by $0.25. The company had revenue of $17.04 million during the quarter, compared to the consensus estimate of $19.42 million. Clovis Oncology had a negative return on equity of 81.34% and a negative net margin of 624.02%. The firm’s revenue for the quarter was up 21746.2% compared to the same quarter last year. During the same quarter in the prior year, the firm posted ($1.83) EPS. equities research analysts predict that Clovis Oncology Inc will post -4.75 EPS for the current fiscal year.
ILLEGAL ACTIVITY NOTICE: “Wells Fargo & Company MN Lowers Position in Clovis Oncology Inc (CLVS)” was reported by American Banking News and is owned by of American Banking News. If you are accessing this story on another site, it was stolen and republished in violation of U.S. and international trademark & copyright law. The original version of this story can be viewed at https://www.americanbankingnews.com/2018/03/12/wells-fargo-company-mn-lowers-position-in-clovis-oncology-inc-clvs.html.
About Clovis Oncology
Clovis Oncology, Inc is a biopharmaceutical company focused on acquiring, developing and commercializing anti-cancer agents in the United States, Europe and other international markets. The Company’s product candidates include Rociletinib, Rubraca (Rucaparib) and Lucitanib. Rucaparib is an oral, small molecule poly adenosine diphosphate (ADP)-ribose polymerase (PARP) inhibitor of PARP1, PARP2 and PARP3 approved as a monotherapy for the treatment of patients with deleterious breast cancer (BRCA) (human genes associated with the repair of damaged deoxyribonucleic acid (DNA)) mutation (germline and/or somatic) associated advanced ovarian cancer.
Want to see what other hedge funds are holding CLVS? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Clovis Oncology Inc (NASDAQ:CLVS).
Receive News & Ratings for Clovis Oncology Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Clovis Oncology and related companies with MarketBeat.com's FREE daily email newsletter.